Cytoglobin (Cygb) is a cellular haemoprotein belonging to the globin family with ambiguous biological functions. Downregulation of Cygb in many cancers is indicative of its tumour-suppressive role. This is the first report showing the cell cycle regulation of Cygb, which was found to peak at G1 and rapidly decline in S phase. Importantly, Skp2-mediated degradation of Cygb was identified as the key mechanism for controlling its oscillating levels during the cell cycle. Moreover, overexpression of Cygb stimulates hypophosphorylation of Rb causing delayed cell cycle progression. Overall, the study reveals a novel mechanism for the regulated expression of Cygb and also assigns a new role to Cygb in cell cycle control.
Tumour suppressors play a crucial role in the regulation of cell cycle. Aberrant expression of these genes contributes towards unrestrained cellular proliferation leading to tumourigenesis [1] . Downregulation of the putative tumour suppressor, Cytoglobin (Cygb), has been reported in a number of human cancers [2] [3] [4] [5] [6] [7] . However, apart from promoter methylation and loss of heterozygosity, the precise mechanism for its low level in cancer cells remains unknown. Since its discovery, Cygb has attracted several investigations to explore its biochemistry, function and implications in human pathologies [8, 9] . Various suggested roles of Cygb include intracellular oxygen storage, oxygen sensing, binding and detoxification of nitric oxide [10] [11] [12] . Its intrinsic catalase and peroxidase activities help in conferring protection against reactive oxygen species during oxidative stress [8, [13] [14] [15] [16] . Cygb has also been implicated in tumour-suppressive functions as the loss of its expression is associated with increased proliferation and transformation potential of cancer cells whereas its overexpression reverted tumourigenicity [5, 17] . Moreover, epigenetic inactivation of Cygb is correlated with poor prognosis in glioma patients [18] . Increased tumour susceptibility of Cygb knockout mice presents yet another evidence in favour of Cygb's tumour suppressor function [17] . Additionally, recent studies on glioma and ovarian cell lines have demonstrated that ectopic expression of Cygb increases the G1/S ratio implying its role in regulating cell cycle progression [19] . However, the exact molecular mechanism underlying the tumour suppressor activity of Cygb is only partially understood. Recent findings from our laboratory also highlight the role of Cygb in DNA damage response and maintenance of genomic stability [20] . These findings support the role of Cygb in cell cycle arrest upon genotoxic stress in a p53-dependent manner. Based on the apparent growth inhibitory functions of the tumour suppressor Cygb, our current study is an attempt to explore its cell cycle-related properties.
Cell cycle transitions are driven by periodic destruction of key cell cycle regulators [21] and ubiquitin proteasome system plays a central role in this process [22] . Among various E3 ligases, Skp2 has drawn much attention as a promising cancer drug target [23] . A significant amount of evidence also indicates that Skp2 is highly oncogenic and often overexpressed in many types of human cancers [24] [25] [26] [27] . Skp2 plays a prominent role in triggering G1/S transition of cell cycle by targeting many tumour suppressors and cyclin inhibitors for degradation [28] [29] [30] [31] [32] . Suggested tumour suppressor designation of Cygb prompted us to investigate the role of Skp2 in the regulation of Cygb during cell cycle. Here, we demonstrate that Cygb is a cell cycleregulated protein. We also provide evidences that Skp2 interacts with Cygb and facilitates its periodic degradation to promote cell cycle progression. Overall, these findings underscore the importance of Cygb in negatively regulating cell growth and proliferation.
Materials and methods
Cell culture, transfection, western blotting and k phosphatase treatment Cells were cultured in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100UÁmL
À1 of penicillin and 100 mgÁmL À1 streptomycin (Invitrogen, Carlsbad, CA) in a humidified incubator with 5% CO 2 atmosphere at 37°C. Transient transfections were performed using Lipofectamine TM 2000 reagent (Invitrogen, Carlsbad, CA) as per manufacturer's instructions in U2OS cells and using calcium-phosphate method in HEK293T cells [33] . The cell extracts were processed as described earlier [34] . Briefly, the medium was changed after 16 h of transfection and the cells were lysed 36 h post-transfection in lysis buffer containing 50 mM Tris-Cl, pH 7.5, 400 mM NaCl, 0.2% Nonidet-P40, protease inhibitors from Roche Applied Science (Mannheim, Germany). Equal amount of extracts were then resolved in SDS/PAGE and subjected to western blotting with appropriate antibodies. For dephosphorylation assay using k phosphatase, equal amount of cell extracts prepared in the absence of phosphatase inhibitors were incubated with 2 units of k phosphatase (New England Biolabs, Ipswich, MA) at 30°C for 1 h. 
Antibodies, constructs and chemicals

Generation of stable cell line and Real Time RT-PCR
Stable line expressing EGFP-Cygb was generated by employing the procedure described elsewhere [35] . The transduced cells were selected using puromycin (1 lgÁmL À1 ) and the generated stable cell line was confirmed by western blotting. For RT-qPCR, total RNA was isolated by using 
Protein degradation assay
Protein degradation assay using cycloheximide (CHX) was conducted as described before [36] . Briefly, transiently transfected cells were incubated with CHX (100 lgÁmL À1 ) and harvested at different time points. The cell extracts were subjected to SDS/PAGE and analysed by western blotting. Densitometric analyses of scanned images were performed using Multi Gauge V3.0 (Fujifilm, Tokyo Midtown, Japan) software. 
Cell synchronization and cell cycle analysis
Co-immunoprecipitation analyses
Cells were transfected with desired plasmids and after 36 h of transfection, lysed using NETN Co-IP lysis buffer containing 150 mM NaCl, 5 mM EDTA, 0.5% NP40, 50 mM Tris-HCl (pH 7.5), 2 mM PMSF (phenylmethanesulfonylfluoride), 2 mM NaF, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Roche, Mannheim, Germany). For immunoprecipitation using M2 agarose (Sigma, St. Louis, MO), 1.5 mg of precleared extract was gently rocked with M2 agarose beads overnight at 4°C. Following incubation, the beads were extensively washed with the lysis buffer and the bound proteins were eluted with 100 lgÁmL À1 Flag peptide followed by SDS/PAGE and western blot detection. For immunoprecipitation with V5 antibody, 1.5 mg of the precleared extract was incubated with 1 lg of V5 antibody for 4 h at 4°C with gentle rocking. This was followed by rocking the complex with Protein G bead suspension for an additional 1 h. The beads were extensively washed with NETN buffer and the bound protein was eluted by using SDS/PAGE sample dye. Beads were spun down and the clear supernatant was resolved by SDS/PAGE and subjected to immunodetection with appropriate antibodies.
In vivo Ubiquitination assay 
Clonogenic assay and cell growth assay
A total of twenty thousand cells were seeded in 60 mm dish and allowed to grow in complete medium. After 7 days, cells were washed with PBS and stained with 0.5% crystal violet in 20% methanol. Excess stain was removed by extensive washing and the number of visible colonies (containing at least 50 cells) was counted. For determining the cell growth rate, 10 000 cells were seeded (in triplicate) in a 24 well culture plate and allowed to grow. Cells were trypsinized and counted after every 24 h for 8 days using a haemocytometer and graph was plotted using values obtained at every alternate day. Data were obtained from three independent cultures and each experiment was repeated three times.
BrdU incorporation assay
BrdU assay was performed by following the protocol published earlier [38] with certain modifications. Briefly, HEK293T cells (1 9 10 6 cellsÁmL À1 ) transfected either with control vector or with EGFP-Cygb were labelled with 10 lM BrdU (Sigma, St. Louis, MO) for 1 h. Cells were washed with PBS, fixed using 4% paraformaldehyde and then permeabilized with PBS containing 0.1% Triton Ò X-100. Acid treatment was carried out first with 1N HCl on ice and then with 2N HCl at RT for 10 min each. Phosphate/citric acid buffer, pH 7.4 was used for neutralization by incubating the cells for 10 min at RT. Cells were stained with anti-BrdU antibody (GE healthcare, Buckinghamshire, UK) followed by incubation with Alexa-Fluor-594-labelled anti-mouse (Invitrogen, Carlsbad, CA). The cells were counterstained with DAPI and mounted on slides using ProLong Ò Gold Antifade. Visualization was done under fluorescent microscope (Nikon-Eclipse-Ti-S, Tokyo, Japan).
Results
Cygb level oscillates during cell cycle
Previous studies have suggested that the loss of Cygb can cause deregulated cellular proliferation and induce tumour susceptibility in mouse model [17] . In view of the growth inhibitory role of Cygb, we wanted to investigate the cell cycle dependence of Cygb degradation. Hence, we examined the abundance of Cygb protein in different phases of the cell cycle by synchronizing U2OS cells stably expressing EGFPCygb at G1/S by double thymidine block. Cells from various time points postrelease were analysed by propidium iodide staining followed by flow cytometry for cell cycle analysis. The cell extracts were also subjected to immunoblotting in order to analyse the alterations in the level of Cygb at different cell cycle phases. As shown in Fig. 1A , FACS data revealed that 75% of cells were in G1 at 0 h of release from thymidine block whereas the S phase cellular population was observed to peak at the 6 h time point. According to the immunoblot result (Fig. 1B) , Cygb protein level remained high at G1/S transition (0 h) which steadily decreased as the cells progressed into the S phase (predominantly by 6 h, 38.38% cells) and reappeared again while exiting from S phase (13 h onwards). Further validation for synchronized cell cycle progression was performed by immunoblotting with cyclin E, a known cell cycleregulated protein, which starts accumulating at G1/S transition. Similar effect was also observed by checking the levels of endogenous Cygb (though signals were weak) following release from nocodazole block, Fig. 1C . As expected, Cygb stabilization was seen at G2/M (0 h) for upto 4 h postrelease from the block, while a visible reduction in its levels was observed at late G1 and S phase (6 h onwards). Cell cycle phases were verified by checking the levels of cyclin B, cyclin E and phospho-histone3 (Fig. 1C) . However, RT-qPCR analysis did not reveal any prominent variations in the Cygb mRNA during the entire cell cycle (Fig. 1D ) unlike the protein levels thereby indicating that in cycling cells, Cygb is largely regulated by posttranslational mechanism. To further assess whether the reduction in Cygb during S phase was due to protein destabilization, U2OS cells stably expressing EGFPCygb were synchronized at G2/M by nocodazole treatment and at G1/S by double thymidine block. The thymidine blocked cells were released for 3 h to enrich the S phase population followed by CHX treatment. Under this condition, the difference in the level of protein detected on the western blot reflects only its protein turnover rate. The half-life was measured by harvesting cells at different time points. As shown in Fig. 1E and graphically depicted in Fig. 1F there was a sharp decline in the stability of Cygb in S phase (t 1/ 2 <30 min) compared to G2/M phase where only 20% reduction was observed even after 90 min of CHX treatment. Furthermore, we investigated whether this decrease in the level of Cygb during cell cycle is regulated by proteasome machinery as it is one of the major systems involved in the turnover of proteins. For this purpose, cells were synchronized at G2/M phase by nocodazole block and at G1/S phase by double thymidine block. Following release from their respective blocking treatments, cells were incubated with the proteasome inhibitor MG132 for 5 h prior to harvesting. The result indicated a rapid decrease in the protein level of Cygb in S phase as compared to G2/M phase ( Fig. 1G ) which was restored upon the addition of MG132, thereby indicating the involvement of proteasome machinery in its degradation during S phase. Nevertheless, the lack of complete recovery of Cygb levels during the S phase in comparison to G2/M after MG132 treatment also suggests that proteasome-mediated degradation may not be the only mechanism responsible for the regulation of Cygb. ). The cells were harvested at indicated times and equal amount of cell lysate were subjected to SDS/PAGE followed by immunoblotting with GFP and b-actin antibodies. (F) The intensity of EGFP-Cygb band was quantified by densitometry and plotted against the time of CHX treatment. Solid line represents remaining levels of Cygb during G2/M phase and dashed line for S phase. Results are plotted as standard error of mean with P value <0.05 between two groups. (G) U2OS cells stably expressing EGFP-Cygb were blocked with nocodazole and double thymidine for 17 h, the thymidine blocked cells were harvested either after mock treatment or after incubation with 20 lM of MG132 for 5 h. Equal amount of cell lysates were analysed by western blotting with GFP and b-actin antibodies. All the experiments were repeated at least thrice with representative images being shown in the figure.
Skp2 induces ubiquitin-dependent degradation of Cygb
As a critical ubiquitin ligase, Skp2 governs the S phase progression through the elimination of key regulatory molecules involved in G1/S phase transition [39] . Therefore, we examined the cell cycle-regulated expression of Cygb and Skp2 in U2OS cells stably expressing EGFP-Cygb synchronized at G0/G1, S phase and G2/M phase. The data showed that Cygb protein was more abundant in G0/G1 as well as in G2/M phase as compared to the S phase. On the contrary, Skp2 levels were maintained high at S phase compared to its level during G0/G1 and G2/M phase ( Fig. 2A) . Thus, these results reveal an inverse correlation between the protein levels of Cygb and Skp2. HEK293T cells ectopically expressing either empty vector or FlagCygb were used to examine the association between Cygb and Skp2 by carrying out co-immunoprecipitation study. Cell lysates were immunoprecipitated with M2 agarose beads followed by western blot analysis (Fig. 2B) . Similar results were obtained when this experiment was repeated in U2OS cells (Fig. S1) . Additionally, reverse co-IP with V5-Skp2 again yielded Flag-Cygb as an interacting partner as shown in Fig. 2C . Altogether, these data supported the idea that Cygb is a potential target of Skp2. To elucidate the importance of Skp2 as a determinant of Cygb stability, we transfected HEK293T cells with fixed amount of Flag-Cygb along with increasing dose of V5-Skp2 and fixed amount of GFP as transfection control. The immunoblot analysis of the steady state levels of Cygb in transfected cell extracts revealed that increasing the expression of Skp2 induced a marked reduction in the protein level of Cygb in a dose-dependent manner as shown in Fig. 2D . To further confirm the Skp2-mediated destabilization of Cygb, we performed halflife assays. For this, HEK293T cells were transfected with Flag-Cygb in the absence or presence of V5-Skp2. Following transfection, the cells were incubated with CHX for various time points and lysates were immunoblotted for detecting Cygb and Skp2. As shown in Fig. 2E and Fig. 2F , a considerable drop in the levels of Cygb was observed from the 8 h time point in presence of V5-Skp2 as opposed to the control cells, which displayed a similar drop in Cygb levels at a later time point (12 h). At the 12 h time point, even though Cygb levels of both the sets seemed to drop, the densitometric values showed significant differences in the turnover rate (Fig. 2F) . Clearly, this difference in Cygb turnover (Fig. 2F) in the presence of Skp2 implies a positive role of Skp2 in destabilization of Cygb.
Since E3 ubiquitin ligases are known to degrade their target proteins via ubiquitination, our next goal was to determine whether Skp2 facilitates ubiquitination of Cygb. To this end, we performed an in vivo ubiquitination assay in HEK293T cells by transfecting relevant plasmids as indicated in the Fig. 2G and 2H, followed by treatment with MG132 for 5 h prior to harvesting. Immunoprecipitation was carried out with Flag antibody and immunoblotting with antibodies against ubiquitin, Flag and V5. The immunoblot analysis showed that ectopic expression of Skp2 enhanced the polyubiquitinated intermediates of Cygb, which appeared as a smear of high molecular weight bands on SDS/PAGE gel in presence of MG132 ( Fig. 2G and 2H ). Figure 2G verifies that the slower migrating bands that were detected after overexpression of Skp2 correspond to the polyubiquitinated forms of Flag-Cygb which appeared to overlap with the laddering pattern of Fig. 2H . These data clearly demonstrate that Cygb is indeed targeted for ubiquitin-mediated degradation by Skp2 ubiquitin ligase.
Dominant negative Skp2 fails to degrade Cygb
The contribution of Skp2 in controlling the abundance of Cygb was further verified by using a dominant negative F-box mutant of Skp2 which is routinely used for studying the Skp2-mediated degradation of its substrates. The V5-Skp2DN was generated by deleting the N-terminal residues from 1 to 153 containing the F-box domain, which is involved in recruiting Skp2 to the SCF complex [40, 41] . Skp2 lacking the F-box domain was shown to function as dominant negative by sequestering the endogenous protein [42, 43] . This property was exploited to determine the significance of endogenous Skp2 in the ubiquitin-mediated degradation of Cygb. Briefly, U2OS cells stably expressing EGFP-Cygb were transfected with increasing dose of V5-Skp2DN. An incremental accumulation of Cygb was observed upon dose-dependent expression of V5-Skp2DN (Fig. 3A) . Further, the inhibitory effect of Skp2DN on the endogenous Skp2 was assessed during S phase of the cell cycle. For this, EGFP-Cygb stably expressing U2OS cells were synchronized by double thymidine block and the cell lysates were analysed by immunoblotting 3 h after being released from the block. The results revealed that overexpression of V5-Skp2DN resulted in the accumulation of Cygb in S phase cells in contrast to the control cells (Fig. 3B) , thereby substantiating the role of Skp2 in the destabilization of Cygb during S phase. Interestingly, a decrease in the cyclin A level was also observed in V5-Skp2DN overexpressing cells which may reflect an impeded S phase progression and an increment in the proportion of G1 phase cells due to stabilization of Cygb [44, 45] . Since Skp2 acts on multiple substrates, such decline may also result from Skp2's effect on other cell cycle regulators. We also examined whether Skp2 deficiency caused by Skp2DN can abrogate the ubiquitination of Cygb. The results of in vivo ubiquitination of Cygb confirmed that while Skp2WT was able to stimulate ubiquitination of Cygb, overexpression of Skp2DN readily abolished this ubiquitin tagging event (Fig. 3C) . Thus, these results demonstrate that Skp2 plays an important role in controlling the proteolytic turnover of Cygb. Additionally, in order to explore the role of Cygb-Skp2 axis in influencing cellular proliferation, we carried out growth curve assay and colony formation assay in HEK293T cells overexpressing FlagCygb together with either V5-Skp2WT or V5-Skp2DN. The expression of these constructs was verified through western blotting (Fig. S2) . The growth curve assay revealed that co-expression of Flag-Cygb and V5-Skp2DN leads to a prominent decrease in cell proliferation rate as compared to V5-Skp2WT and Flag-Cygb co-expression (Fig. 3D) . Similarly, cells expressing Flag-Cygb and V5-Skp2DN displayed a 50% drop in their colony forming ability in comparison to the cells expressing Flag-Cygb and V5-Skp2WT as shown in Fig. 3E and graphically represented in Fig. 3F . Together, these results indicate that the downregulation of Cygb by Skp2 is responsible for enhanced cellular proliferation.
Cygb interacts with Skp2 through its C-terminal region
In order to identify the region of Cygb involved in mediating protein-protein interaction with Skp2, we created N-terminal and C-terminal Cygb mutants as depicted in Fig. 4A . HEK293T cells were transfected with V5-Skp2 alone or together with Flag-CygbWT, Flag tagged N-terminal-Cygb mutant and Flag tagged C-terminal mutant of Cygb, respectively. The cell lysates were immunoprecipitated with M2 agarose beads followed by immunoblotting with V5 and Flag antibodies. The results revealed a substantial interaction between V5-Skp2 and Flag-Cygb C-terminal mutant (weakly expressed) as shown in Fig. 4B . Interestingly, this interaction was found to be stronger than that of wild-type Cygb. In contrast, despite higher expression of the N-terminal mutant of Cygb (than the C-terminal Cygb mutant), it showed negligible binding to Skp2. Therefore, the results suggest that the C-terminal domain of Cygb plays a major role in mediating the interaction with Skp2. 
Cygb overexpression impairs cell proliferation by delaying cell cycle progression
Based on literature, Skp2 targets are found to be key negative regulators of cell cycle [24, 28, 30, 32] . Moreover, our data showing low level of Cygb during S phase and its degradation by Skp2 are also suggestive of the antiproliferative functions of Cygb. Therefore, we intended to assess the effect of Cygb on cellular proliferation by performing a growth curve assay. For this purpose, equal number of cells expressing control vector and EGFP-Cygb were plated and each set was counted everyday for 8 days and representative graph was plotted for data of every second day. Notably, Cygb-expressing cells exhibited a significantly slower rate of proliferation when compared with the control cells (Fig. 5A) . The inhibitory effect of Cygb on cell proliferation was further confirmed by colony formation assay, which showed around 60% reduction in the number of colonies in Cygb overexpressing cells (Fig. 5B and 5C ). Next, we reasoned that the reduced growth rate of Cygb expressing cells may be due to delayed G1 to S phase transition. Therefore, we examined the influence of Cygb on the phosphorylation status of Rb as it is one of the major determinants of S phase progression. U2OS cells stably expressing control vector and Cygb were either mock treated or incubated with k phosphatase followed by western blot analysis. The analysis revealed a reduction in the level of slower migrating hyperphosphorylated form of Rb in the presence of Cygb and this band was lost after k phosphatase treatment indicating that it indeed is the hyperphosphorylated form of Rb (Fig. 5D) . Additionally, as observed in Fig. 5E , the overexpression of Flag-Cygb also reduced the levels of cyclin E and cyclin D. These results suggest that Cygb may be able to negatively influence cell proliferation by modulating the status of cell cycle regulatory factors. Since Cygb overexpression increased the level of hypophosphorylated Rb, we extended our study to examine the effect of Cygb on G1 to S phase transition. U2OS cells expressing either the empty vector or EGFP-Cygb were synchronized by double thymidine block and allowed to progress through the cell cycle and extracts were prepared at different time points. Western blot analysis of these extracts (Fig. 5F ), demonstrated that the hyperphosphorylated form of Rb starts appearing as early as 2 h postrelease of thymidine block in control cells. Conversely, Cygb-overexpressing cells exhibited a delayed appearance of hyperphosphorylated Rb from 4 h after the removal of thymidine block indicating a lag in the cell cycle progression. In order to further confirm the negative role of Cygb in S phase progression, we performed FACS analysis of U2OS cells transiently transfected either with EGFP or with EGFP-Cygb and examined the percentage of cells in G1 and S phase (Fig. 5G) . As expected, overexpression of EGFP-Cygb led to an overall increase in the G1 phase cells (69.44% vs 66.5% of control cells) with a concomitant decrease in S phase population (19.3% vs 22.9% of control cells) as compared to the control EGFP-expressing cells. Moreover, we also performed FACS analysis of U2OS cells and EGFP-Cygb stably expressing U2OS cells synchronized using double thymidine block and analysed their cell cycle profile at 3 h and 6 h after release from the block. As expected, EGFP-Cygb expressing cells were observed to progress more slowly into S phase than the control U2OS cells.
At 3 h postrelease, 24% of the EGFP-Cygb U2OS cells were seen in S phase which further increased to 38% by 6 h. However, the control U2OS cells showed 33% of S phase population at 3 h which declined to 28% by 6 h suggesting that while the control U2OS cells seem to have exited from S phase by 6 h, a considerable population of U2OS EGFP-Cygb cells were still seen in S phase. Additionally, BrdU incorporation assay also corroborated with reduced cellular proliferation ability of EGFP-Cygb overexpressing cells (Fig. 5H) . HEK293T cells transfected either with control vector or with EGFP-Cygb were pulsed with BrdU for 1 h after 48 h of transfection and immunostained with anti-BrdU antibody for analysing BrdU incorporation. The analysis revealed about 18.6% of EGFP-Cygb overexpressing cells to exhibit BrdU incorporation, whereas the control cells had 28.18% of BrdU positive cells. Taken together, our results clearly demonstrate that Cygb is a negative regulator of cell cycle.
Discussion
Multiple investigations have promoter hypermethylation and loss of heterozygosity as the suggested mechanisms for the low abundance of Cygb in cancers. However, an intuition regarding the existence of some other mechanism for its downregulation was evident from previous research on other tumour suppressors [46, 47] . Mechanistic studies in this direction that are aimed at understanding the regulation of Cygb in human cells and elucidation of pathways affecting its functions related to cell proliferation would be of considerable importance for the treatment of cancer. In this regard, we were interested to investigate the antiproliferative effect of Cygb, by first analysing the cell cycle profile of its expression. Here, we provide evidence that Cygb protein levels rapidly decline at S phase and reappear towards its exit. Moreover, we show that post-translational mechanisms are largely responsible for regulating Cygb's abundance. Such expression pattern is essentially exhibited by negative regulators of cell cycle such as p27, p21, etc., and thus favours the tumour-suppressive function of Cygb. Furthermore, half-life experiments revealed that Cygb protein is highly susceptible to proteolysis during S phase compared to the G2/M phase. Additionally, the accumulation of Cygb protein upon MG132 treatment implied a role of proteasome pathway in its destruction.
Skp2 is overexpressed in numerous human cancers and is predictive of poor prognosis [25] . The Skp2 ubiquitin ligase acts as the key propeller of G1/ S transition by promoting the proteolysis of cell cycle regulators which interfere with S phase progression such as p21, p27, etc. [24, 28, 48] . Our results showing an inverse correlation between the expression levels of Cygb and Skp2 indicate that Cygb may be a potential target of Skp2. We also show that Cygb interacts with Skp2 through its C-terminal domain. Our analysis of Cygb turnover in the presence of Skp2 and studies involving Skp2DN strongly suggest that Cygb is indeed a specific substrate of Skp2 and that this degradation occurs during S phase. Furthermore, this is also the first report showing post-translational modification (Skp2-mediated ubiquitination) of Cygb. This is a prominent and interesting finding of our study. In this context, it may be envisaged that high expression of Skp2 in human malignancies such as lung, oral and breast cancers may also account for low level of Cygb in these tumours. Therefore, overexpression of Skp2 or deregulation of ubiquitin proteasome system may downregulate Cygb resulting in premature entry into S phase and uncontrolled proliferation. However, we cannot rule out the possibility that Cygb just like p53, another tumour suppressor protein, may also serve as a substrate for other E3 ligases in a context-dependent manner. It is important to consider that the elimination of Cygb may be critical for the cell cycle advancement and its sustained expression may result in cell cycle arrest. Therefore, it is likely that multiple mechanisms other than the proteasomal pathway may be at play to regulate Cygb expression. In this regard, ablation of endogenous Skp2 activity by forced expression of Skp2DN mutant, yielded accumulated levels of Cygb even in absence of MG132 with a concomitant decrease in the level of cyclin A, the well-known S phase promoter (Fig. 3B) [44, 45] . These results are consistent with recent findings in glioma and ovarian cell lines where overexpression of Cygb was shown to increase the G1/S ratio [19, 49] . The results (Fig. 3D, 3E and 3F) also highlight the importance of Cygb-Skp2 axis in controlling cellular proliferation. Our observation of Cygb overexpression causing retardation of cell growth and proliferation (Fig. 5A-C, 5G and 5H ) is yet another evidence that is in line with literature and our recent findings on Cygb-mediated cell cycle arrest [19, 20, 49] . Our previous work also identified the transcription factor, p53 as a novel interactor of Cygb and this investigation not only supports the cell cycle-related functions of Cygb but also alludes to its nuclear functions. Though mostly reported to be cytoplasmic, possibilities of nuclear localization of Cygb were also shown earlier by Guens et al. [50] and Mammen et al. [51] . Additionally, being a hypoxia-responsive haemoprotein, ROS scavenging properties of Cygb might help in conferring cytoprotection and stress adaptation at physiological levels of oxidative stress. However, Cygb may induce cell cycle arrest by stabilizing p53 tumour suppressor protein and by bringing about hyperphosphorylation of Rb at high levels of oxidative stress, while unmanageable levels of oxidative injury may trigger p53-mediated apoptotic pathways [14] .
Another intriguing finding of the current study is that high expression of Cygb reduces the extent of Rb phosphorylation which is a key propeller of G1/S transition [52] . This prompts us to propose that Cygb delays S phase entry through Rb-mediated sequestration of E2F. Alternatively, Cygb may prevent Rb phosphorylation by interfering with CDK activities, an aspect that requires further investigation.
Based on our findings and existing literature, it is conceivable that in G1 phase, high levels of Cygb lead to hyperphosphorylation of Rb which may prevent premature entry into S phase. However, upon reception of mitogenic cues, Skp2 ligase machinery recognizes and earmarks Cygb for proteasome-mediated degradation; thereby enabling the cells to enter into S phase. In conclusion, our findings support the tumour suppressor activity of Cygb and provide novel insights into the mechanism underlying the regulation of Cygb protein abundance through Cygb-Skp2 axis. The findings of this research may provide interesting avenues to devise novel improved strategies to treat cancer.
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